relatlimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies 5514 1673516-98-7

Description:

MoleculeDescription

Molfile

Synonyms:

  • relatlimab
  • relatlimab-rmbw
  • opdualag
  • BMS-986016
  • BMS986016
  • ONO-4482
Relatlimab is a human IgG4 monoclonal antibody that binds to the LAG-3 receptor, blocks interaction with its ligands, including MHC II, and reduces LAG-3 pathway-mediated inhibition of the immune response. Antagonism of this pathway promotes T cell proliferation and cytokine secretion. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human IgG4 monoclonal antibody that binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and reduces PD-1 pathwaymediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone. In murine syngeneic tumor models, LAG-3 blockade potentiates the anti-tumor activity of PD-1 blockage, inhibiting tumor growth and promoting tumor regression.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 18, 2022 FDA BRISTOL MYERS SQUIBB
Sept. 15, 2022 EMA BRISTOL-MYERS SQUIBB PHARMA EEIG

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FY02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Combinations of monoclonal antibodies and antibody drug conjugates
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000082082 Immune Checkpoint Inhibitors
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000194002 Lymphocyte Activation Gene-3 Antagonists
FDA EPC N0000194003 Lymphocyte Activation Gene-3 Blocker
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FY Combinations of monoclonal antibodies and antibody drug conjugates 3 drugs
nivolumabpertuzumabtrastuzumab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Unresectable or metastatic melanoma indication 443493003
Advanced melanoma with tumour cell PD-L1 expression below 1% indication 443493003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Lymphocyte activation gene 3 protein Tumour-associated antigen ANTAGONIST Kd 9.92 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:756524 CHEBI
CHEMBL3990044 ChEMBL_ID
C000721227 MESH_SUPPLEMENTAL_RECORD_UI
9536 IUPHAR_LIGAND_ID
DB14851 DRUGBANK_ID
42656311000001103 SNOMEDCT_US
4041299 VANDF
4041300 VANDF
C4724799 UMLSCUI
D11350 KEGG_DRUG
10735 INN_ID
357919 MMSL
40561 MMSL
d09869 MMSL
018998 NDDF
AF75XOF6W3 UNII
2596772 RXNORM
C000729737 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OPDUALAG HUMAN PRESCRIPTION DRUG LABEL 2 0003-7125 INJECTION 4 mg INTRAVENOUS BLA 28 sections